Recently, newly designed IL-21-armored CAR-NK cells were found to show significantly greater IFN-γ and TNF-α production and greater degranulation than IL-15-armored counterparts; this resulted in greater activity of CD19-CAR-NK cells against CD19-positive lymphoma in vitro (85). This evidence concerns the gene CD19 and lymphoma.